There's been a lot of talk in pharma circles about making sure that their drug development programmes and clinical trials are patient-centric – but what can be done for pe
Each year, pharma and life sciences invest large amounts of time and money in creating content designed to attract HCPs and call them to action.
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector. But, al
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessme